Cogent Biosciences (COGT) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cogent Biosciences is the larger company by market cap ($5.23 billion vs $4.64 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | MANE |
|---|---|---|
| Share price | $30.14 | $110.95 |
| Market cap | $5.23B | $4.64B |
| 1-day change | -0.79% | +1.83% |
| YTD return | -15.15% | — |
| 1-year return | +95.21% | — |
| 5-year return | +226.19% | — |
| EPS (TTM) | $-2.16 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-328.94M | $-70.00M |
| 52-week high | $43.73 | $131.24 |
| 52-week low | $13.78 | $32.00 |
| Distance from 52-week high | -31.08% | -15.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.20% | +47.36% |
| Average volume | 1.94M | 730.99K |
| Shares outstanding | 173.52M | 41.78M |
| Employees | 258 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
COGT vs MANE FAQ
Which is bigger, Cogent Biosciences or Veradermics?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.23B compared with $4.64B for Veradermics (MANE).
Are Cogent Biosciences and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.